[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608754":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":18,"responsibleParty":31,"collaborators":33,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":7,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",null,[9],{"name":10,"affiliation":5,"role":11},"Myriam Alexander, PHD","PRINCIPAL_INVESTIGATOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[19],{"facility":20,"status":21,"city":22,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":7},"Research Site","RECRUITING","Frankfurt","Germany","DE",{"type":26,"coordinates":27},"Point",[28,29],10.53333,49.68333,{"lat":29,"lon":28},{"type":32,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[34],{"name":35,"class":6},"ICON plc","100608754","the-eplontersen-pregnancy-and-lactation-outcomes-study-100608754",false,"NCT07205666","The Eplontersen Pregnancy and Lactation Outcomes Study","The Eplontersen Pregnancy and Lactation Outcomes Study (EPPRO): A Descriptive Safety Study of Pregnant and Lactating Individuals and Their Offspring Exposed to Eplontersen","EPPRO","Inclusion Criteria:\n\n* all pregnancy and\u002For lactation cases with exposure to eplontersen and a diagnosis of an approved indication for treatment with eplontersen\n* all adverse event reports in infants in the first 12 months of age that are or can be linked to pregnancy or lactation reports in individuals previously diagnosed with an approved indication and exposed to eplontersen during pregnancy or lactaction\n\nExclusion Criteria:\n\n* all case reports considered invalid (i.e. minimum data is not provided at first report nor follow-up), or where reporter indicates that they do not wish to be contacted to obtain follow-up information, or the reporter\u002Fpatient cannot be identified","ALL",{"count":46,"type":47},10,"ESTIMATED","OBSERVATIONAL","The overall objective of this DPSS is to describe the occurrence of pregnancy and maternal complications, adverse effects on the developing fetus and neonate, and adverse effects on the infant associated with exposure to eplontersen during pregnancy and\u002For lactation.",[51],"Transthyretin Amyloidosis",[53,54,55,56],"Eplontersen","pregnancy","Wainua","Wainzua","2026-06-18",{"date":59,"type":60},"2026-06-22","ACTUAL",{"date":62,"type":60},"2025-11-30",{"date":64,"type":47},"2035-12-30",{"name":5,"class":6},1]